Herceptin was the most obvious candidate to establish proof of concept—especially for the part of the treatment where it is administered as monotherapy, Schmidt adds. “That is mainly the case ...

Deemed as the “drug that changed the breast cancer treatment landscape,” Herceptin has saved millions of women's lives ...

The research, which comes from several groups including Genentech, makers of the prevailing anti-HER2 treatment, has researchers questioning whether current ... By the late ’90s, a drug called ...

The PD-1 checkpoint inhibitor cancer treatment is fast becoming the backbone ... biosimilar launch in Europe is a version of Roche’s Herceptin (trastuzumab). Biosimilar companies are poised ...

These patients should be given Herceptin drug for treatment. Health Secretary Patricia Hewitt has already ordered the National Institute for Health and Clinical Excellence (NICE), the drugs ...

The latest Herceptin biosimilar is branded as Kanjinti (trastuzumab-anns) and is approved in all indications of the reference product. These are for the treatment of HER2-overexpressing adjuvant ...

Healthcare organisations, including the Kenyan Network of Cancer Organisations (KENCO) and the NCD Alliance Kenya (NCDAK), have condemned the deteriorating health services for cancer patients, calling ...

Hence she and her family had to start a fundraising campaign to pay for her treatment privately. She has now started a year-long course of Herceptin at the Christie Hospital in Manchester.

They were pleading for “access - not excuses” when it came to Genentech’s promising new treatment for metastatic breast cancer: a drug called trastuzumab, also known as Herceptin®.

Thanks to the growing understanding of cancer biology we have seen considerable progress from chemotherapy, to pioneering drugs like Herceptin ... paradigms in cancer treatment that may ...

In the small group of study patients at M.D. Anderson who received Herceptin, says Buzdar, none so far has developed any heart problems almost two years after treatment. Some doctors have ...